We analyzed RASSF1A and NORE1A methylation and BRAF mutation in 89 thyroid tumors, 42 non-neoplastic thyroid tissues and three thyroid tumor cell lines using polymerase chain reaction (PCR), methylation-specific PCR, Western blotting and DNA sequencing in order to study thyroid tumor pathogenesis and progression. RASSF1A promoter methylation was present in all three thyroid cell lines and in 27/78 (35%) of benign and malignant thyroid tumors. We showed for the first time that there was generally good agreement between RASSF1A methylation status and RASSF1A protein expression. We also examined for the first time NORE1A promoter region methylation in thyroid cell lines and primary tumors and showed that two of three thyroid cell lines were methylated in the NORE1A promoter region, while all primary thyroid tumors analyzed (n ¼ 51) were unmethylated. BRAF mutation was present in 38% of papillary thyroid carcinomas (PTC), including 20% of PTC with a follicular variant pattern and 67% of the tall cell variant of PTC. Hyalinizing trabecular tumors (n ¼ 23), which had nuclear features similar to PTC, did not have BRAF mutations, indicating that the presence of BRAF mutations can help to separate these two tumor types. Phospho-MEK expression was increased in the NPA cell line, which had a BRAF mutation, supporting the importance of the BRAF pathway alterations in PTC pathogenesis. These results indicate that RASSF1A epigenetic changes are an early event in thyroid tumor pathogenesis and progression and that NORE1A methylation is uncommon in primary thyroid tumors. BRAF mutation occurs later in thyroid tumor progression and is restricted mainly to PTC and anaplastic thyroid carcinoma.
Thyroid tumor development and progression is regulated by various oncogenes and tumor suppressor genes, only a few of which have been identified to date.
1,2 RAS association domain family protein 1 (RASSF1) gene, located on chromosome 3p21.3, 3 is a recently described tumor suppressor gene whose expression is regulated epigenetically. RASSF1A and RASSF1C, two major transcript variants, are expressed in a wide variety of normal tissues. 3 Exogenous expression of RASSF1A in a cell line lacking expression decreased in vitro colony formation and in vivo tumorigenicity. 4 Mutant RASSF1A had significantly reduced growth suppression activity. 5 The reintroduction of RASSF1A expression suppressed the growth of various tumor cell lines, including those from the prostate and lungs. 3, 6 RASSF1A has a role as a tumor suppressor gene, since this gene blocked cell cycle progression and inhibited cyclin D1 accumulation. 7 Loss of RASSF1 expression has been correlated with methylation of the CpG-island promoter sequence of RASSF1 gene. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] RASSF1A has been reported to be inactivated in lung, breast, kidney, prostate, ovary, colon, thyroid and other cancers. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] A few groups have examined the inactivation of RASSF1A in thyroid tumors and found inactivation of RASSF1A in many types of thyroid cancer. [15] [16] [17] However, RASSF1A protein expression has not been correlated with RASSF1A gene methylation, an analysis that should provide insight into the functional consequences of RASSF1A methylation.
Vavvas et al 18 identified a novel potential Ras effector target Nore1 and showed that Nore1 directly interacted with Ras in vitro in a GTP-dependent manner, an interaction that required an intact Ras effector domain. NORE1A and NORE1B are two spliced variants, which are expressed in most normal tissues. 19 Methylation of the CpG islands of NORE1A and NORE1B has been examined in only a few primary tumors. 19 NORE1A promoter was methylated in some breast, lung, colorectal and kidney cell lines, while the NORE1B promoter was unmethylated in the same tumor cell lines. 20 NORE1 methylation has not been examined in thyroid cell lines or tissues.
Three Raf families of serine/threonine kinases have been identified as raf-1 (c-RAF, A-raf and B-raf) in human. [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] They function in the transduction of mitogenic signals from the cell membrane to the nucleus and mediate cell proliferation and differentiation. 31 RAS function is not required for the growth of cancer cell lines with the BRAF V600E T1799A (previously reported as V599E T1796A) mutation. 32 Kumar et al 33 reported that the mutational hot spot codon and nucleotide incorrectly reported in earlier reports as 599 and 1796 were correctly located at codon 600 and nucleotide 1799. BRAF V600E mutation has been detected in various tumors, including malignant melanoma, nevi, colon cancer and thyroid cancers. Although papillary thyroid carcinoma (PTC) and hyalinizing trabecular tumor (HTT) have common nuclear cytologic features and can be confused, the role of BRAF mutation, if any, in the development of HTT is unknown. [32] [33] [34] [35] [36] In this study, we analyzed normal thyroid tissues and thyroid tumors for methylation of RASSF1A and NORE1A genes and for BRAF V600E gene mutation to determine the role of these genes in thyroid cancer pathogenesis and progression.
Materials and methods

Human Tissues and Cell Lines
In all, 89 thyroid tumors and 42 non-neoplastic thyroid tissues were used in this study (Table 1) . Non-neoplastic tissues adjacent to the tumor areas of PTC (n ¼ 34), follicular thyroid carcinomas (FTC) (n ¼ 3) and medullary thyroid carcinomas (MTC) (n ¼ 5) were analyzed. The tumors included 42 PTC, four FTC, five MTC, 12 anaplastic thyroid carcinomas (ATC), 23 HTT and three follicular adenomas (FA). There were 45 formalin-fixed paraffin-embedded tissues among a total of 89 tumors (Table 1) . Approval of the Mayo Clinic Institutional Review Board was obtained for this study.
Three human thyroid cancer cell lines were used. NPA and TPC1 cells derived from PTCs were kindly provided by Dr Yuri E Nikiforov (Department of Pathology, University of Cincinnati College of Medicine, Cincinnati, OH, USA). TT1 was derived from an FTC and established in our laboratory as a cell line. NPA was used as a positive control for BRAF V600E mutation. [36] [37] [38] TPC1 had a RET/PTC-1 rearrangement. 37 NPA, TPC1 and TT1 cells were grown at 371C in a humidified incubator with 5% CO 2 . NPA was cultured in RPMI Medium1640 supplemented with 10% fetal bovine serum, 1% antibiotic-antimycotic and 1 mg/l insulin. TPC1 and TT1 were cultured in Dulbecco's modified Eagle medium, 15% horse serum heated inactivated, 2.5% fetal bovine serum, 1% antibiotic-antimycotic and 1 mg/l insulin. All cell culture reagents were obtained from Life Technologies, Inc., Grand Island, NY, USA.
Genomic DNA Extraction
Genomic DNA was extracted from the thyroid tissues using the following procedure: frozen tissues were cut into small pieces with a scalpel, mixed with 2 ml of TEN buffer (10 mM Tris-HCl, pH 7.4, 25 mM EDTA, 10 mM NaCl) and 100 ml of 20% sodium dodecyl sulfate (SDS, Sigma, St Louis, MO, USA). Proteinase K (Roche Diagnostics Corporation, Indianapolis, IN, USA) was added to achieve a final concentration of 0.2 mg/ml and the tissues were incubated overnight at 501C. After incubation, 1 volume of phenol/chloroform/isoamyl alcohol (Invitrogen, Carlsbad, CA, USA) was added and thoroughly mixed well. The tissues were centrifuged and the aqueous layer containing the DNA was transferred to fresh tubes. One volume of chloroform/isoamyl alcohol (1:1) was added and well mixed. After centrifugation the aqueous layers were transferred to a fresh tube. Genomic DNA was precipitated by the addition of 2.5 volumes of 100% ethanol and the samples were centrifuged. The DNA pellets were washed by adding 70% ethanol, centrifuged and re-suspended in Molecular Biology Grade water (Eppendorf, Westbury, NY, USA). The concentrations of genomic DNA were measured by optical density with a spectrophotometer (Spectronic Genesys 8 Thermo Spectronic, Rochester, NY, USA).
Cultured cells were trypsinized, collected by centrifugation and washed with phosphate-buffered saline (PBS) twice. Genomic DNA from the cell lines was extracted using the same procedure. Genomic DNA from paraffin-embedded specimens was prepared from four to six 10-mm-thick sections. The sections were deparaffinized and gradually dehy- Epigenetic changes and BRAF mutations in thyroid tumors N Nakamura et al drated and air-dried. DNA was isolated using the procedure described above.
Methylation-Specific Polymerase Chain Reaction (MS-PCR)
The bisulfite method was used to detect DNA methylation of RASSF1A and NORE1A. 39, 40 Genomic DNA (2 mg) was treated with bisulfite, which converts unmethylated cytosine to uracil, from an EZ DNA Methylation Kit, according to the manufacturer's suggestions (Zymo Research, Orange, CA, USA). The CpGenome Universal Methylated DNA (1 mg) (Chemicon International, Inc., Temecula, CA, USA) was used as positive control for methylated DNA and as negative control for unmethylated DNA. Genomic DNA (2 mg) of the HeLa cell line was used as positive control for unmethylated DNA.
Four primer sets for RASSF1A and NORE1A were prepared for methylated DNA and unmethylated DNA ( Table 2 ). The PCR mix included: 0.2 mM dNTPs, 0.2 mM of each primer, 1 Â Easy-A Reaction Buffer and 0.75 U Easy-A High-Fidelity PCR Cloning Enzyme (Stratagene, La Jolla, CA, USA). For MS-PCR, 1 ml of the bisulfite-modified DNA was used for each sample.
Step-down PCR was performed to improve the specificity for RASSF1A gene. A stepdown PCR protocol for methylated DNA of RASS-F1A was used as follows: 951C for 2 min, Â 1 cycle; 951C for 30 s, 641C for 30 s and 721C for 30 s, Â 2 cycles; 951C for 30 s, 621C for 30 s and 721C for 30 s, Â 2 cycles; 951C for 30 s, 601C for 30 s and 721C for 30 s, Â 20 cycles for DNA from frozen tissues, or Â 30 cycles for DNA from paraffin sections and a final extension at 721C for 10 min. A step-down PCR protocol for unmethylated DNA of RASSF1A was used similar to that for methylated DNA of RASS-F1A, except that 28 cycles of amplification were used for DNA from paraffin sections. For NORE1A gene, MS-PCR protocol for methylated DNA was used as follows: 951C for 10 min, Â 1 cycle; 951C for 1 min, 621C for 1 min and 721C for 2 min, Â 30 cycles for DNA from frozen tissues, or Â 46 cycles for DNA from paraffin sections and a final extension at 721C for 10 min. MS-PCR protocol for unmethylated DNA of NORE1A gene was used same as above, except that the annealing temperature was 641C. Molecular Biology Grade Water was used as negative control of both MS-PCR reactions.
In all, 10 ml of each PCR product was electrophoresed on Ready Gels of 10% TBE for polyacrylamide electrophoresis (Bio-Rad Laboratories, Hercules, CA, USA), stained with ethidium bromide and visualized under UV light.
Polymerase Chain Reaction (PCR)
PCR primers to amplify BRAF exon 15 (BRAF set 1) are shown in Table 2 . PCR was performed in 50 ml of reaction mixture using 100 ng of genomic DNA for frozen tissues or cultured cells, and 500-2000 ng of genomic DNA from paraffin sections. The reaction mixture contained 100 pM of each primer, 0.2 mM of dNTPs (Roche), 2 mM MgCl 2 , 1 Â reaction buffer and 1.25 U Taq DNA polymerase (Promega, Madison, WI, USA). The reaction mixture was subjected to initial denaturation at 951C for 10 min, 40 cycles of denaturation at 951C for 1 min, annealing at 561C for 1 min, extension at 721C for 1 min and final extension at 721C for 10 min on the GeneAmp PCR system 9700 (PE Applied Biosystems, Foster City, CA, USA). Molecular Biology Grade Water (Eppendorf) was used as negative control.
BRAF Mutation Analysis by Direct Sequencing
PCR products (20 ml) were electrophoresed on a 1.2% agarose gel (Invitrogen life technologies), stained with ethidium bromide and visualized under UV light. The PCR product obtained with BRAF set 2 used for sequencing only. RASSF1A-M and NORE1A-M: primers used for methylated DNA, RASSF1A-U and NORE1A-U: primers used for unmethylated DNA. F: forward primer, R: reverse primer.
Epigenetic changes and BRAF mutations in thyroid tumors N Nakamura et al BRAF primer set 1 was extracted with an Ultrafree-DA (Millipore Corporation, Bedford, MA, USA) and purified with a Microcon YM-100 (Millipore Corporation). The same primers were used for DNA sequencing. The cases with BRAF mutation were re-sequenced using the BRAF set 2 primers ( . Anti-b-actin antibody (1:1000 dilution, Sigma) was used to check for equal loading on the gel as previously reported. [43] [44] [45] The reaction products were detected with enhanced chemiluminescence (Amersham, Arlington Heights, IL, USA). Densitometric analysis of the bands was carried out with a Fluor-S multimager (Bio-Rad). Results were expressed as relative densitometry units, and all data were normalized with b-actin. A linear response was obtained using different amounts of proteins on the gel.
Results
RASSF1A Methylation and Protein Expression
Analysis of the methylation status of the RASSF1A promoter region showed hypermethylation of the RASSF1A gene in all three thyroid tumor cell lines (NPA, TPC1 and TT1) ( Table 3 and Figure 1a) .
Analysis of RASSF1A methylation in PTC and matching normal tissues showed that 32% of PTC was methylated (Figure 1a and Table 4 ). There was generally good agreement between unmethylated RASSF1A and protein expression detected by Western blotting. The 39 kDa RASSF1A protein was detected in all non-neoplastic thyroids and in most unmethylated tumors (Figure 1b) . However, the amount of RASSF1A protein in different samples was variable. Normal thyroid tissues generally expressed more RASSF1A protein than the unmethylated tumors. The thyroid cell lines, which were methylated, did not express RASSF1A protein (Figure 1b) . Hypermethylation of RASSF1A in primary tumors was variable with PTC (32%), FTC (100%), MTC (40%), FA (33%) and HTT (25%) ( Table 4 and Figure 2 ). Non-neoplastic thyroid tissues were all unmethylated (Table 4) . Among the subtypes of PTC, a percentage of classical PTC smaller than the follicular variant patterned tumors was methylated (Table 5 ). The methylation frequencies of the RASSF1A gene were 25% (7/28 cases) in classic PTC and 60% (3/5 cases) in PTC follicular variant. The one case of PTC tall-cell variant was also methylated (Table 5 ).
NORE1A Methylation
The NPA cell line was completely hypermethylated in the promoter region of NORE1A, while the TPC1 cell line was heterozygous, with a methylated and an unmethylated band for NORE1A (Table 3 and Figure 3 ). The TT1 cell line was unmethylated for NORE1A (Table 3 and Figure 3 ). All normal and neoplastic human thyroid tissues were unmethylated in the promoter region of NORE1A (Table 4 and Figure 3 ).
BRAF Mutation
Analysis of the three thyroid cell lines showed that the NPA cells had BRAF V600E mutation, but PTC-1 and TT1 cells were negative for BRAF V600E mutations (Table 3) . BRAF mutations were identified in 16 cases of PTC at the V600E site. All mutations involved the same change at nucleotide position 1799, where thymine was replaced by adenine, resulting in the substitution of valine at position 600 for glutamic acid (Figure 4) . One case of ATC had a BRAF mutation (10%) ( Table 4) . None of the other tumor types had a BRAF V600E mutation, including 23 cases of HTT ( Figure 5 and Table 4 ). BRAF V600E mutation was not detected in the 42 cases of matching non-neoplastic thyroid tissues from the PTC ( Table 4) . Analysis of the subtypes of PTC with BRAF mutation showed that 11 cases were classic PTC (35%), while only one of five follicular variant carcinomas (20%) had a BRAF V600E mutation. Most (four of six) tall-cell variant carcinomas (67%) had BRAF V600E mutations (Table 5 ). The same sequencing Epigenetic changes and BRAF mutations in thyroid tumors N Nakamura et al results for BRAF mutations were obtained by using two different sets of BRAF primers (Table 2) .
Western Blot Analysis of MAPK and MEK
Analysis of the NPA and TPC1 cell lines showed equal-size bands for MAPK and phospho-MAPK (Figure 6a ). The NPA cell line, which harbored a BRAF V600E mutation, showed increased expression of phospho-MEK (Figure 6b ). The TPC1 cell line, which did not have a BRAF V600E mutation, had a weaker band for phospho-MEK compared to MEK.
Discussion
Analysis of RASSF1A in normal and neoplastic thyroid tissues showed that all non-neoplastic thyroid tissue was unmethylated, while RASSF1A was hypermethylated in both benign and malignant tumors. Methylation studies of RASSF1A have shown that this gene is one of the most commonly methylated tumor suppressor genes, 3, 4 and the few studies of RASSF1A in thyroid tumors [15] [16] [17] have not examined the wide spectrum of benign tumors and more aggressive well-differentiated tumors reported in this study. Schagdarsurengin et al 15 detected RASSF1A in benign adenomas (44%), FTC tumors (75%) and PTC tumors (20%). In our study, the finding of methylated RASSF1A in both benign and malignant thyroid tumors Epigenetic changes and BRAF mutations in thyroid tumors N Nakamura et al suggests that it is an early event in thyroid tumorigenesis. This is supported by our finding of unmethylated RASSF1A only in the non-neoplastic thyroid tissues and methylated RASSF1A in the benign tumors. RASSF1A inactivation has been associated with increased tumor cell proliferation via Cyclin D1 and increased apoptosis via MST1, so these mechanisms may also be important in thyroid tumor progression. 7 We show for the first time that in thyroid tumors there is generally good agreement between unmethylated RASSF1A and protein expression and that thyroid tumors that were methylated usually did not express RASSF1A protein, while most of the unmethylated tumors expressed RASSF1A proteins. These observations confirm the functional role of RASSF1A protein in signal transduction and cell proliferation in thyroid neoplasms.
Our study of NORE1A methylation in thyroid tissues is the first reported analysis of NORE1A in thyroid tumors. The results showed that two of three thyroid cell lines were methylated in the NORE1A promoter region. However, all of the thyroid tumors analyzed as well as the 42 non-neoplastic thyroids were unmethylated. The presence of NORE1A methylation in thyroid cell lines and not in the primary tumors is similar to earlier reports in gliomas, nasopharyngeal carcinomas and small-cell carcinomas of the lungs in which cell lines from these tumors were methylated, while all of the primary tumors were unmethylated. 20, 46, 41 These findings may be analogous to the finding of a higher rate of methylation in metastatic compared to primary breast cancers including the RASSF1A gene, and the possibility that promoter methylation may confer survival advantages as with cells grown in vitro. 47 It is also possible that the cell culture conditions may change the promoter methylation status of the cultured cells. Silencing of NORE1A by methylation is probably related to RASSF1A silencing, since both of these genes are members of the Ras effector group. 18, 20 BRAF V600E mutation was detected in 38% of PTC and in 10% of ATC, but not in other tumor types in this study. This mutation has previously been detected in 29-69% of PTC and in some of the ATC. 17, [36] [37] [38] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] Reports of BRAF V600E mutation in ATC have been quite variable. 37, 50, 51, [53] [54] [55] [56] 61 These results may vary in part with the methods used to detect the mutation. Nikiforova et al 51 reported that there was no difference in various techniques in the detection of BRAF V600E mutations, using LightCycler PCR fluorescence melting curve analysis, singlestrand conformational polymorphism and direct sequencing. BRAF V600E mutation is highly specific for PTC. However, variation in the incidence of mutations was dependent on the type of PTC. BRAF V600E mutation was detected in 67% of tall-cell PTC and in 20% of follicular variant of PTC in this study in agreement with earlier reports , 52, 55, 56, 60 indicating that BRAF V600E mutation is more common in more aggressive thyroid tumors.
Although an inverse relationship between BRAF V600E mutation and hypermethylation of RASS- Figure 3 Methylation-specific PCR analysis of NORE1A. NPA and TPC1 cell lines were methylated at the promoter region of NORE1A.
All primary thyroid tumors were unmethylated of the promoter region of NORE1A. HeLa-DNA (unmethylated) and the methylated CpGenome Universal DNA were used as controls for MS-PCR. Water was used as negative control.
Epigenetic changes and BRAF mutations in thyroid tumors N Nakamura et al F1A was suggested by Xing et al, 17 we did not observe this relationship in our study. The relationship between BRAF V600E mutation and other mutations in PTC has also been examined. Xu et al 38 reported that 38% of their cases had both of BRAF mutations and RET/PTC rearrangements. Nikiforova et al 57 observed that 4% of their cases had BRAF mutation and RET/PTC rearrangement. Understanding the interaction of these various genes during thyroid tumor progression will require further studies. Our observations of increased expression of phosphorylated MEK in the NPA cell line that has BRAF mutations supports the hypothesis that this pathway is important for PTC pathogenesis.
An important practical implication of our study is that HTT (n ¼ 23) did not have BRAF mutations. Trovisco et al also observed the absence of BRAF mutation in a smaller series (n ¼ 5) of HTT. 52 HTTs Figure 5 Hematoxylin-and-eosin-stained case of a PTC (a) and an HTT (b). Although these HTT share some cytologic features with PTC, they were all negative for BRAF V600E mutations. Figure 4 PCR amplification followed by nucleotide sequencing of the PCR products to detect BRAF V600E mutations. The matching non-neoplastic thyroid tissue showed a wild-type peak (top), while a PTC from the same case showed a BRAF V600E mutation. T-A transversion at nucleotide 1799 (bottom).
Epigenetic changes and BRAF mutations in thyroid tumors
N Nakamura et al have many nuclear features in common with PTC and the distinction between HTT and PTC may be difficult in cytological and tissue specimens. Our findings suggest that molecular analysis for BRAF in cases in which it is not possible to distinguish between a HTT and PTC in cytological or biopsy specimens will be a very useful molecular assay. In summary, analysis of the epigenetic changes of RASSF1A and NORE1A in thyroid tumor indicates that methylation of RASSF1A is an early event in thyroid tumor pathogenesis and that NORE1A methylation is uncommon in primary thyroid tumors. BRAF point mutation occurs later in thyroid tumor progression and is restricted to PTC and some ATCs. Phospho-MEK 1/2 expression was increased in the NPA cell line, which had a BRAF mutation supporting the importance of the BRAF pathway in the development of PTC.
